Latest VRCA News

• Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts - GlobeNewswire Inc. - Wed, May 15, 2024 11:30 AM
• Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga - Tue, May 14, 2024 1:01 PM
• Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates - Zacks Investment Research - Mon, May 13, 2024 12:40 PM
• Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results - GlobeNewswire Inc. - Mon, May 13, 2024 11:30 AM
• Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates - Zacks Investment Research - Thu, May 9, 2024 12:10 PM
• Verrica Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewswire Inc. - Thu, May 9, 2024 11:30 AM
• Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024 - GlobeNewswire Inc. - Wed, May 8, 2024 11:30 AM
• Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates - Zacks Investment Research - Tue, May 7, 2024 9:25 PM
• Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last? - Zacks Investment Research - Mon, May 6, 2024 10:35 AM
• Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength? - Zacks Investment Research - Thu, Apr 25, 2024 9:48 AM